XML 16 R7.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
May 18, 2023
Dec. 31, 2024
Dec. 31, 2023
Operating activities      
Net income (loss)   $ 28,507 $ (237,892)
Adjustments to reconcile net income (loss) to net cash used in operating activities:      
Depreciation and amortization   5,276 3,791
Stock-based compensation expense   27,802 43,110
Impairment of out-license asset and remeasurement of CVR liability, net   6,772  
Loss on debt extinguishment   12,630  
Gain on Sale Transactions, net (Note 6)   (176,589)  
Inventory write-downs, net   14,143 52,595
Non-cash interest expense from amortization of debt and other financial liabilities discount and issuance costs   4,159 2,407
Non-cash operating lease expense   1,394 2,476
Change in fair value of derivatives   5,043 375
Other non-cash adjustments, net   (5,471) (4,920)
Changes in operating assets and liabilities:      
Trade receivables, net   149,350 (150,683)
Inventory   (31,952) (46,734)
Prepaid manufacturing   4,664 2,027
Other prepaid, current and non-current assets   (838) 16,155
Accounts payable   (3,938) 23,760
Accrued rebates, fees and reserves   (6,065) 113,105
Accrued compensation   1,549 (5,373)
Accrued and other current and non-current liabilities   (56,876) 10,917
Net cash used in operating activities   (20,440) (174,884)
Investing activities      
Proceeds from maturities of investments in marketable securities   6,200 144,360
Proceeds from sale of investments in marketable securities   8,688 13,282
Cash and cash equivalents acquired as part of the Surface Acquisition     6,997
Milestone payment to Junshi Biosciences   (12,500)  
Purchases of investments in marketable securities     (19,507)
Other investing activities, net   110 (492)
Net cash provided by investing activities   230,321 144,640
Financing activities      
Proceeds from Revenue Purchase and Sale Agreement, net of issuance costs   36,486  
Proceeds from issuance of common stock upon exercise of stock options   291 694
Proceeds from purchase under the employee stock purchase plan   926 1,809
Taxes paid related to net share settlement   (2,476) (3,587)
Other financing activities, net   (248) (1,034)
Net cash (used in) provided by financing activities   (186,974) 69,600
Net increase in cash, cash equivalents and restricted cash   22,907 39,356
Cash, cash equivalents and restricted cash at beginning of period   103,343 63,987
Cash, cash equivalents and restricted cash at end of period   126,250 103,343
Supplemental disclosure of cash flow information      
Cash paid for interest   25,376 37,857
Income taxes refunded, net   (114) (118)
Supplemental disclosures of non-cash activities      
Capitalized and accrued milestone payment during the period to Junshi Biosciences     25,000
Stock issued under Optional Stock Purchase Agreement     8,179
Non-cash employee bonuses settled in common stock   4,408  
CIMERLI Sale      
Investing activities      
Cash received from Sale (Note 6)   187,823  
YUSIMRY Sale      
Investing activities      
Cash received from Sale (Note 6)   40,000  
2027 Term Loans      
Financing activities      
Repayment of Term Loan, premiums and exit fees   (260,387)  
2029 Term Loans      
Adjustments to reconcile net income (loss) to net cash used in operating activities:      
Non-cash interest expense from amortization of debt and other financial liabilities discount and issuance costs   201  
Financing activities      
Proceeds from 2029 Term Loan, net of debt discount and issuance costs   36,979  
ATM Offering      
Financing activities      
Proceeds from issuance of common stock, net of issuance costs   $ 1,455 18,093
Public Offering      
Financing activities      
Proceeds from issuance of common stock, net of issuance costs $ 53,600   $ 53,625